Thursday, December 22, 2011
Takeda Pharmaceutical will integrate two wholly-owned subsidiaries, Takeda San Diego (TSD) and Takeda San Francisco (TSF) on January 1, 2012. TSD will become the surviving company and change its name to Takeda California (TCAL) the same day. Keith Wilson, current president of TSD, will become the president of the new company.
Takeda Pharmaceutical and Intellikine have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.
Institutional Review Board Services (IRB Services) has been awarded full accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
Exelixis has granted to Merck an exclusive worldwide license to its PI3K-delta research and development program, including XL499, the company’s most advanced preclinical PI3K-delta inhibitor and other related compounds. Under the agreement, Merck will have a worldwide exclusive license and have sole responsibility to research, develop, and commercialize compounds originating from the program.
Warnex has entered into an agreement with a private company to sell its wholly-owned analytical services division, which provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Closing of this transaction will take place upon the execution of definitive documentation, which is expected to occur on or about January 15, 2012